OBJECTIVE: Few studies have investigated irisin and FGF21 to elucidate the role of these hormones to regulate 'beiging' in HIV-infected patients. DESIGN:Fifty HIV-infected subjects with the metabolic syndrome were previously recruited and randomized to receive lifestyle modification (LSM) and/or metformin over 12 months. In the current study, we assessed FGF21 and irisin at baseline and after intervention. In addition, we assessed circulating FGF21 and irisin in relationship to brown adipose tissue (BAT) gene expression in dorsocervical subcutaneous fat biopsies from 13 HIV-infected subjects. RESULTS: At baseline, prior to intervention, HIV-infected subjects demonstrated increased log FGF21 (2·13 ± 0·06 vs 1·98 ± 0·05 pg/ml, P = 0·05) and log irisin (0·33 ± 0·02 vs 0·17 ± 0·04 μg/ml, P = 0·003) compared with healthy controls well matched based on waist circumference. After 12 months, HIV-infected subjects randomized to LSM demonstrated a relative reduction in FGF21 compared with those not randomized to LSM (-10 [-35,22] vs 40 [0,94] %change, P = 0·01). Changes in FGF21 were inversely associated with improved parameters of energy homoeostasis, including increased REE (ρ = -0·34, P = 0·046) and max VO2 (ρ = -0·38, P = 0·02), and reduced RQ (ρ = 0·40, P = 0·02) among all HIV-infected subjects. Increased UCP-1 (r = 0·75, P = 0·003), DIO2 (r = 0·58, P = 0·04) and CideA (r = 0·73, P = 0·01) gene expression in dorsocervical fat was significantly associated with FGF21 in HIV-infected subjects. CONCLUSION: HIV-infected subjects with metabolic complications demonstrate increases in FGF21 in relationship to BAT gene expression. Relative reductions in FGF21 in those receiving long-term LSM relate to overall improvements in energy expenditure parameters. In contrast, irisin levels are elevated in HIV-infected subjects, but are not influenced by LSM nor associated with BAT gene expression.
RCT Entities:
OBJECTIVE: Few studies have investigated irisin and FGF21 to elucidate the role of these hormones to regulate 'beiging' in HIV-infectedpatients. DESIGN: Fifty HIV-infected subjects with the metabolic syndrome were previously recruited and randomized to receive lifestyle modification (LSM) and/or metformin over 12 months. In the current study, we assessed FGF21 and irisin at baseline and after intervention. In addition, we assessed circulating FGF21 and irisin in relationship to brown adipose tissue (BAT) gene expression in dorsocervical subcutaneous fat biopsies from 13 HIV-infected subjects. RESULTS: At baseline, prior to intervention, HIV-infected subjects demonstrated increased log FGF21 (2·13 ± 0·06 vs 1·98 ± 0·05 pg/ml, P = 0·05) and log irisin (0·33 ± 0·02 vs 0·17 ± 0·04 μg/ml, P = 0·003) compared with healthy controls well matched based on waist circumference. After 12 months, HIV-infected subjects randomized to LSM demonstrated a relative reduction in FGF21 compared with those not randomized to LSM (-10 [-35,22] vs 40 [0,94] %change, P = 0·01). Changes in FGF21 were inversely associated with improved parameters of energy homoeostasis, including increased REE (ρ = -0·34, P = 0·046) and max VO2 (ρ = -0·38, P = 0·02), and reduced RQ (ρ = 0·40, P = 0·02) among all HIV-infected subjects. Increased UCP-1 (r = 0·75, P = 0·003), DIO2 (r = 0·58, P = 0·04) and CideA (r = 0·73, P = 0·01) gene expression in dorsocervical fat was significantly associated with FGF21 in HIV-infected subjects. CONCLUSION:HIV-infected subjects with metabolic complications demonstrate increases in FGF21 in relationship to BAT gene expression. Relative reductions in FGF21 in those receiving long-term LSM relate to overall improvements in energy expenditure parameters. In contrast, irisin levels are elevated in HIV-infected subjects, but are not influenced by LSM nor associated with BAT gene expression.
Authors: Josep Lloreta; Pere Domingo; Ramón M Pujol; Juan A Arroyo; Núria Baixeras; Xavier Matias-Guiu; Montserrat Gilaberte; Maria A Sambeat; Sergi Serrano Journal: Virchows Arch Date: 2002-10-24 Impact factor: 4.064
Authors: Jordi P Guallar; José M Gallego-Escuredo; Joan C Domingo; Marta Alegre; Joan Fontdevila; Esteban Martínez; Emma L Hammond; Pere Domingo; Marta Giralt; Francesc Villarroya Journal: AIDS Date: 2008-03-12 Impact factor: 4.177
Authors: Pere Domingo; José M Gallego-Escuredo; Joan C Domingo; Maria del Mar Gutiérrez; Maria G Mateo; Irene Fernández; Francesc Vidal; Marta Giralt; Francesc Villarroya Journal: AIDS Date: 2010-11-13 Impact factor: 4.177
Authors: Pontus Boström; Jun Wu; Mark P Jedrychowski; Anisha Korde; Li Ye; James C Lo; Kyle A Rasbach; Elisabeth Almer Boström; Jang Hyun Choi; Jonathan Z Long; Shingo Kajimura; Maria Cristina Zingaretti; Birgitte F Vind; Hua Tu; Saverio Cinti; Kurt Højlund; Steven P Gygi; Bruce M Spiegelman Journal: Nature Date: 2012-01-11 Impact factor: 49.962
Authors: Allison R Webel; Trevor Jenkins; Christopher T Longenecker; Marianne Vest; Christine Horvat Davey; Jackson Currie; Rebecca Darrah; Paul Litman; Vitor Hugo Fernando de Oliveira; Richard A Josephson Journal: J Assoc Nurses AIDS Care Date: 2019 Jul-Aug Impact factor: 1.354
Authors: Allison Ross Eckard; Heather Y Hughes; Nancy L Hagood; Mary A O'Riordan; Danielle Labbato; Julia C Kosco; Sarah E Scott; Grace A McComsey Journal: J Acquir Immune Defic Syndr Date: 2020-04-15 Impact factor: 3.771
Authors: Nicola Morrice; George D Mcilroy; Seshu R Tammireddy; Jennifer Reekie; Kirsty D Shearer; Mary K Doherty; Mirela Delibegović; Phillip D Whitfield; Nimesh Mody Journal: Sci Rep Date: 2017-03-03 Impact factor: 4.379
Authors: Ricardo Moure; Pere Domingo; Joan Villarroya; Laura Gasa; José M Gallego-Escuredo; Tania Quesada-López; Samantha Morón-Ros; Alberto F Maroto; Gracia M Mateo; Joan C Domingo; Francesc Villarroya; Marta Giralt Journal: Antimicrob Agents Chemother Date: 2018-05-25 Impact factor: 5.191
Authors: Greg S Gojanovich; Denise L Jacobson; Carly Broadwell; Brad Karalius; Brian Kirmse; Mitchell E Geffner; Jennifer Jao; Russell B Van Dyke; Elizabeth J McFarland; Margarita Silio; Marilyn Crain; Mariana Gerschenson Journal: PLoS One Date: 2021-12-31 Impact factor: 3.240
Authors: Neeti Agarwal; Dinakar Iyer; Pradip Saha; Aaron R Cox; Yan Xia; Netanya S Utay; Anoma Somasundaram; Ulrich Schubert; Jordan E Lake; Sean M Hartig; Ashok Balasubramanyam Journal: Diabetes Date: 2021-07-07 Impact factor: 9.337